KRN4884

KRN4884 is dissolved in DMSO as a 10 mM stock solution, and diluted in the bath solution. The final concentration of DMSO to which cells are exposed is less than 0.1%^[1].
To quantitatively analyze the effect of KRN4884 or other compounds, channel activity is expressed as NP_oi. NP_oi is calculated by integrating a 5- to 15-s continuous current record during the steady effect of each drug. The concentration-response curve for KRN4884 is obtained by normalizing NP_oi to that obtained by superfusing with the ATP-free bath solution, and fit to a Hill equation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rats^[2]
Five-week old male Sprague-Dawley (Crj; CD) rats are obtained and housed in a temperature-controlled environment with a 12 h daily light cycle with free access to water and chow (CE-2). At 6-weeks old, the animals are assigned to vehicle, Clofibrate (160 mg/kg) or KRN4884 (3 mg/kg) treatment groups. The drug is given daily, by gavage for 10 days at 2 mL/kg as a suspension in 0.5% (w/v) carboxymethyl cellulose. Systolic blood pressure is determined 1 h after administration on day 9 with the tail cu. method by use of a sphygmomanometer. Four hours after the final administration of the drug or vehicle on day 10, non-fasting blood is collected from an abdominal aorta of each rat under ether anaesthesia. Serum is provided for lipid analysis. Epididymal adipose tissue, thigh muscle, and liver are removed and weighed, then immediately immersed in liquid nitrogen and stored at -80°C until use. Epididymal adipose tissue and thigh muscle are used for determining lipoprotein lipase (LPL) activity and the liver is used for de- termining hepatic triglyceride lipase (HTGL) activity.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.